Adjuvant treatment with programmed cell death receptor-1 inhibitor pembrolizumab is an effective adjuvant treatment for stage III/IV melanoma
1. Five-year disease-free survival was greater in patients who had ≤10% viable tumour or brisk tumour-infiltrating lymphocytes 2. Overall survival ...